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Fumarate hydratase (FH) encodes a Krebs cycle 
enzyme which is mutated in hereditary leiomyomatosis and 
renal cell cancer (HLRCC). Fumarate is a potent inhibitor 
of a class of enzymes, 2-oxoglutarate (2OG) oxygenases, 
that require oxygen, non-haem Fe(II), and 2OG for activity. 
Importantly, loss of FH function has been shown to result 
in elevated levels of fumarate in cells and tumors. Recent 
work has demonstrated that fumarate-mediated inhibition 
of a sub-class of 2OG oxygenases, the hypoxia-inducible 
factor prolyl hydroxylase enzymes (HIF-PHDs), causes 
stabilisation of HIF and the upregulation of a broad range 
of HIF-target genes, including those that stimulate cell 
growth and angiogenesis, which may in turn contribute to 
tumorigenesis [1]. Previously we generated a conditional 
Fh1 (the ortholog of human FH) knockout mouse and 
showed that kidney-specific deletion of Fh1 recapitulated 
important aspects of the human disease, including 
activation of HIF and the development of hyperplastic 
renal cysts [2]. HIF dysregulation following inactivation 
of the FH tumor suppressor gene has therefore been 
hypothesised as a plausible mechanism for HLRCC 
tumorigenesis.
In addition to inhibiting 2OG oxygenases, fumarate 
modifies  cysteine  residues  in  multiple  proteins  to 
form S-(2-succinyl)-cysteine (2SC) and this chemical 
modification,  termed  succination,  can  have  important 
functional consequences, such as the inactivation of 
glyceraldehyde-3-phosphate dehydrogenase in both 
an in vivo and in vitro setting [3]. Of potential clinical 
importance, we have reported recently that FH-deficient 
cells and tumors specifically exhibit high levels of 2SC 
that are absent in normal cells and tissues, thus providing 
a potential diagnostic biomarker and an alternative 
candidate or parallel mechanism for tumorigenesis [4].
In last month’s edition of Cancer Cell, we demonstrate 
through multiple genetic crosses in mice, that neither the 
presence of Hif, nor the absence of Phds, are required for 
renal cyst formation in an Fh1-deficient background and 
that surprisingly, loss of Hif-1α actually exacerbates the 
cystic phenotype [5]. Furthermore, we show that murine 
Fh1 deficient renal cysts, mouse embryonic fibroblasts 
and human FH-deficient cells and tissues exhibit a striking 
upregulation of the antioxidant signalling pathway 
mediated through Nuclear factor (erythroid-derived 2)-
like 2 (NRF2) as a direct consequence of FH inactivation 
and independent of HIF/PHD signalling [5].
NRF2  has  been  identified  as  a  master  regulatory 
molecule controlling the adaptive response of cells to 
oxidative and electrophilic stress by interaction and 
activation of multiple NRF2 target genes that contain 
antioxidant response elements [6]. Cellular levels of 
NRF2 are controlled by Kelch-like ECH-associated 
protein 1 (KEAP1). In our work and the accompanying 
manuscript by Ooi and colleagues it is shown by tandem 
mass  spectrometry  that  fumarate  modifies  critical 
cysteine residues (Cys155 and Cys288) within KEAP1 
by succination, abrogating its ability to ameliorate 
antioxidant signaling [5, 7]. 
We therefore postulate that loss of FH leads to an 
accumulation  of  fumarate  that  modifies  key  cysteine 
residues in KEAP1 preventing it from binding NRF2. 
We propose that dysregulation of NRF2, rather than 
activation HIF, may be an alternative candidate pathway 
in tumorigenesis associated with loss of FH.
Studies of HLRCC, resulting from the loss of FH in 
cells, have revealed a complex interplay between genetic 
mutation and dysregulation of cellular metabolism. 
Given the resurgence of interest in the metabolic switch 
associated with cancer cells proposed many years ago by 
Warburg, HLRCC affords a new paradigm to investigate 
the importance of alterations in cellular metabolism and 
cancer.
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